Profile data is unavailable for this security.
About the company
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. The Company uses its precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a potentially registrational Phase 2 trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore substantially improve the clinical overall response rate (ORR) and has the potential to enable expedited drug development. Its preclinical program, ACR-2316, is advancing in IND-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
- Revenue in USD (TTM)0.00
- Net income in USD-60.39m
- Incorporated2018
- Employees58.00
- LocationAcrivon Therapeutics Inc480 Arsenal Way, Suite 100WATERTOWN 02472United StatesUSA
- Phone+1 (617) 207-8979
- Fax+1 (302) 636-5454
- Websitehttps://acrivon.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Candel Therapeutics Inc | 0.00 | -37.94m | 247.40m | 42.00 | -- | 19.24 | -- | -- | -1.31 | -1.31 | 0.00 | 0.4381 | 0.00 | -- | -- | 0.00 | -63.82 | -- | -76.57 | -- | -- | -- | -- | -- | -- | -73.91 | 0.6254 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Century Therapeutics Inc | 2.24m | -136.67m | 248.54m | 152.00 | -- | 0.9797 | -- | 111.20 | -2.30 | -2.30 | 0.0377 | 3.06 | 0.0053 | -- | -- | 14,703.95 | -32.26 | -- | -34.19 | -- | -- | -- | -6,115.12 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| TriSalus Life Sciences Inc | 18.51m | -63.28m | 249.92m | 112.00 | -- | -- | -- | 13.50 | -1.84 | -1.84 | 0.5991 | -0.982 | 0.7758 | 1.30 | 7.24 | 165,267.90 | -247.43 | -- | -17,440.77 | -- | 85.93 | -- | -318.95 | -- | 1.25 | -13.69 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Aldeyra Therapeutics Inc | 0.00 | -37.54m | 250.14m | 10.00 | -- | 2.08 | -- | -- | -0.6375 | -0.6375 | 0.00 | 2.02 | 0.00 | -- | -- | 0.00 | -22.78 | -36.79 | -25.71 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1123 | -- | -- | -- | 39.47 | -- | -- | -- |
| 2Seventy Bio Inc | 100.39m | -217.57m | 253.43m | 274.00 | -- | 0.9777 | -- | 2.52 | -4.41 | -4.41 | 2.04 | 5.04 | 0.1643 | -- | 5.84 | 366,375.90 | -35.61 | -- | -40.20 | -- | 83.15 | 91.76 | -216.73 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Agenus Inc | 156.31m | -245.97m | 253.97m | 389.00 | -- | -- | -- | 1.62 | -13.95 | -13.95 | 8.74 | -8.13 | 0.4297 | -- | 10.94 | 401,832.90 | -70.78 | -55.02 | -194.81 | -115.31 | 98.01 | -- | -164.69 | -102.92 | -- | -1.64 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| Pyxis Oncology Inc | 0.00 | -73.79m | 256.37m | 50.00 | -- | 1.57 | -- | -- | -1.87 | -1.87 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -38.32 | -- | -45.03 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.87 | -- | -- | -- |
| Foghorn Therapeutics Inc. | 34.16m | -98.43m | 260.08m | 116.00 | -- | -- | -- | 7.61 | -2.35 | -2.35 | 0.8137 | -1.83 | 0.0989 | -- | -- | 294,439.70 | -28.50 | -31.35 | -34.11 | -35.69 | -- | -- | -288.17 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 260.61m | 49.00 | -- | 5.86 | -- | 3,217.35 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
| Acrivon Therapeutics Inc | 0.00 | -60.39m | 261.18m | 58.00 | -- | 1.57 | -- | -- | -2.73 | -2.73 | 0.00 | 5.38 | 0.00 | -- | -- | 0.00 | -37.80 | -- | -40.30 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
| Verastem Inc | 0.00 | -87.37m | 262.19m | 73.00 | -- | 4.56 | -- | -- | -4.07 | -4.07 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -71.39 | -62.70 | -88.82 | -75.18 | -- | -- | -- | -406.17 | -- | -- | 0.3379 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| Werewolf Therapeutics Inc | 19.94m | -37.37m | 263.55m | 47.00 | -- | 2.13 | -- | 13.22 | -1.05 | -1.05 | 0.5595 | 2.85 | 0.119 | -- | 4.82 | 424,319.20 | -22.30 | -- | -25.62 | -- | -- | -- | -187.37 | -- | -- | -- | 0.2609 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Sanara Medtech Inc | 64.99m | -4.30m | 267.39m | 107.00 | -- | 5.90 | -- | 4.11 | -0.5219 | -0.5219 | 7.85 | 5.25 | 0.9635 | 1.90 | 8.37 | 607,381.70 | -6.58 | -17.73 | -8.17 | -22.07 | 87.92 | 88.08 | -6.83 | -17.13 | 1.04 | -18.75 | 0.1786 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Poseida Therapeutics Inc | 64.70m | -123.43m | 270.43m | 330.00 | -- | 2.57 | -- | 4.18 | -1.38 | -1.38 | 0.7175 | 1.08 | 0.2068 | -- | 7.15 | 196,069.70 | -39.45 | -40.70 | -49.32 | -47.72 | -- | -- | -190.76 | -233.49 | -- | -14.93 | 0.361 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
| Vanda Pharmaceuticals Inc. | 192.64m | 2.51m | 272.37m | 203.00 | 106.73 | 0.4941 | 49.35 | 1.41 | 0.0439 | 0.0439 | 3.35 | 9.47 | 0.3004 | 11.60 | 5.69 | 948,965.50 | 0.3912 | 6.61 | 0.4547 | 7.62 | 92.32 | 90.55 | 1.30 | 15.18 | 4.92 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Akebia Therapeutics Inc | 194.62m | -51.93m | 272.47m | 167.00 | -- | -- | -- | 1.40 | -0.2778 | -0.2778 | 1.04 | -0.1572 | 0.6512 | 2.22 | 4.89 | 1,165,407.00 | -17.37 | -37.42 | -28.19 | -56.00 | 78.76 | 69.13 | -26.68 | -82.25 | 1.03 | -7.64 | 8.46 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
Data as of May 02 2024. Currency figures normalised to Acrivon Therapeutics Inc's reporting currency: US Dollar USD
59.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 11 Apr 2024 | 8.36m | 27.08% |
| Perceptive Advisors LLCas of 11 Apr 2024 | 5.36m | 17.37% |
| Citadel Advisors LLCas of 31 Dec 2023 | 1.65m | 5.34% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 888.13k | 2.88% |
| Marshall Wace LLPas of 31 Dec 2023 | 597.47k | 1.94% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 516.02k | 1.67% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 467.48k | 1.51% |
| Federated Global Investment Management Corp.as of 31 Dec 2023 | 226.38k | 0.73% |
| Geode Capital Management LLCas of 31 Dec 2023 | 189.20k | 0.61% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 133.28k | 0.43% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
